128 related articles for article (PubMed ID: 37817675)
1. Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.
Wang X; Fu T; Sun W
J Oncol Pharm Pract; 2024 Jan; 30(1):228-234. PubMed ID: 37817675
[TBL] [Abstract][Full Text] [Related]
2. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
3. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
4. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
Hua Y; Huang X; Li C; Gao N
Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
[TBL] [Abstract][Full Text] [Related]
5. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy plus camrelizumab affects peripheral CD8 T-cell differentiation subsets expressing PD-1, TIGIT, and CTLA-4 in esophageal squamous cell carcinoma.
Guo Z; Zhang K; Wei X; Li Y; Ma X; Li Y; Han D; Du Q; Zhang T; Chen X; Wei H; Yan C; Zhang W; Pang Q; Wang P
J Leukoc Biol; 2023 Jan; 113(1):11-17. PubMed ID: 36822161
[TBL] [Abstract][Full Text] [Related]
7. Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma.
Yang Y; Li J; Till BG; Wang J; Zhang B; Wang H; Huang H; Li T; Gao Q; Li H; Wang Z
Front Oncol; 2021; 11():728253. PubMed ID: 34778042
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.
Li L; Lou A; Yu J
Ann Palliat Med; 2021 Jul; 10(7):8460-8466. PubMed ID: 34044548
[TBL] [Abstract][Full Text] [Related]
9. Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.
Kunimasa K; Isei T; Nakamura H; Kimura M; Inoue T; Tamiya M; Nishino K; Kumagai T; Nakatsuka SI; Endo H; Inoue M; Imamura F
Invest New Drugs; 2018 Dec; 36(6):1138-1142. PubMed ID: 29947012
[TBL] [Abstract][Full Text] [Related]
10. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract][Full Text] [Related]
11. Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X; Wu T; Hong Y; Fan Q; Ren Z; Guo Y; Yang X; Shi P; Yang J; Yin X; Luo Z; Xia J; Zhou Y; Xu M; Liu E; Jiang G; Li S; Zhao F; Ma C; Ma C; Hou Z; Li J; Wang J; Wang F
Lancet Gastroenterol Hepatol; 2022 Mar; 7(3):245-253. PubMed ID: 34998471
[TBL] [Abstract][Full Text] [Related]
12. Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR-1210), a novel anti-PD-1 antibody.
Wang X; Zhang B; Chen X; Mo H; Wu D; Lan B; Li Q; Xu B; Huang J
Thorac Cancer; 2019 Jun; 10(6):1395-1401. PubMed ID: 31017739
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
14. Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer.
Yan C; Huang H; Zheng Z; Ma X; Zhao G; Zhang T; Chen X; Cao F; Wei H; Dong J; Tang P; Jiang H; Wang M; Wang P; Pang Q; Zhang W
Front Immunol; 2023; 14():1138054. PubMed ID: 37275884
[TBL] [Abstract][Full Text] [Related]
15. Comparison of dynamic changes in the peripheral CD8
Wei H; Li Y; Guo Z; Ma X; Li Y; Wei X; Han D; Zhang T; Chen X; Yan C; Zhou J; Pang Q; Wang P; Zhang W
Front Immunol; 2022; 13():1060695. PubMed ID: 36479110
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study.
Yang P; Zhou X; Yang X; Wang Y; Sun T; Feng S; Ma X
World J Surg Oncol; 2021 Nov; 19(1):333. PubMed ID: 34809658
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
[No Abstract] [Full Text] [Related]
19. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
[TBL] [Abstract][Full Text] [Related]
20. Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.
Wang D; Zhang S; Ding P; Zhao Y; Zhang X; Zhao Q
Iran J Immunol; 2020 Jun; 17(2):167-171. PubMed ID: 32602470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
